144 related articles for article (PubMed ID: 11107528)
1. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
2. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
[TBL] [Abstract][Full Text] [Related]
3. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Akakura K; Akimoto S; Ohki T; Shimazaki J
Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
[TBL] [Abstract][Full Text] [Related]
7. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
11. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
Iguchi H; Ikeuchi T; Kai Y; Yoshida H
Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
13. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
15. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
Murakoshi M; Ikada R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
[TBL] [Abstract][Full Text] [Related]
19. Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention.
Dutkiewicz S; Stepień K; Witeska A
Mater Med Pol; 1995; 27(2):71-3. PubMed ID: 8935194
[TBL] [Abstract][Full Text] [Related]
20. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]